Lead text placeholder. Lorem ipsum dolor sit amet, consectetur adipisicing elit.


  • "A Phase 1 Study to Assess Safety and Tolerability of REGN5837, an Anti-CD22 x Anti-CD28 Costimulatory Bispecific Monoclonal Antibody, in Combination with Odronextamab, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with Aggressive B-cell Non-Hodgkin Lymphomas (ATHENA-1)"
  • A multicenter open-label randomized Phase II study to evaluate the efficacy and  safety  of  MB-CART2019.1  compared  to standard  of care therapy  in patients  with  relapsed/refractory  Diffuse  Large  B  Cell  Lymphoma,  who  are not eligible for High Dose Therapy and AutologousStem Cell Transplantation
  • A Phase 1/2 Open-label, Multicenter Study Evaluating the Safety and Efficacy of KITE-363, an Autologous Anti-CD19/CD20 CAR T-cell Therapy, in Subjects With Relapsed and/or Refractory B-cell Lymphoma CAR-T
  • "A Phase 1 / 2 Open-Label, Multi-center study of Lenzilumab and Axicabtagene Ciloleucel in Subjects with Relasped or Refractory Large B-Cell Lymphoma (Zuma-19)" CAR-T
  • A Phase 2, Single-Arm, Multi-Cohort, Multi-Center Trial to Determine the Efficacy and Safety of JCAR017 in Adult Subjects with Aggressive B-Cell Non-Hodgkin Lymphoma
  • "A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of\nthe Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (anti-LAG-3 mAb)\nAdministered Alone or in Combination with REGN2810 (anti-PD-1 mAb) in Patients with\nAdvanced Malignancies\n"
  • "NA\nIndication: Hematology Healthy Volunteer\nAdditional Indication Details:NHL\n\nProposal received date:-26-May-2015 Proposal Due date:09-Jun-2015"
  • Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  • A phase 1/2, open-label, single arm, multicohort, multicenter trial to evaluate the safety and efficacy of JCAR017 in pediatric subjects with relapsed/refractory B-ALL and B-NHL (TRANSCEND PEDALL)